Elam Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 2.20 M
as on 11-12-2024
- Company Age 34 Year, 18 Days
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 16.54 Cr
as on 11-12-2024
- Revenue -46.50%
(FY 2022)
- Profit -68.21%
(FY 2022)
- Ebitda -65.45%
(FY 2022)
- Net Worth 1.47%
(FY 2022)
- Total Assets 7.00%
(FY 2022)
About Elam Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.20 M.
The company has closed loans amounting to ₹16.54 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Tejas Jetani and Mavjibhai Jetani serve as directors at the Company.
- CIN/LLPIN
U24232GJ1990PTC014736
- Company No.
014736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 1990
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Elam Pharma Private Limited offer?
Elam Pharma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Bird Food, Poultry & Animal Food, Animal Feed Supplement, Insecticides and Pesticides, Termiticide, Industrial Chemicals & Supplies, Chemical Intermediates, Textile, Dyeing & Finishing Chemical, Textile Chemical.
Who are the key members and board of directors at Elam Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tejas Jetani  | Director | 12-Feb-2022 | Current |
| Mavjibhai Jetani | Director | 05-Dec-1990 | Current |
Financial Performance of Elam Pharma.
Elam Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 46.5% decrease. The company also saw a substantial fall in profitability, with a 68.21% decrease in profit. The company's net worth moved up by a moderate rise of 1.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elam Pharma?
In 2022, Elam Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Oct 2007 | ₹6.53 Cr | Satisfied |
State Bank Of India Creation Date: 15 Oct 2007 | ₹7.01 Cr | Satisfied |
State Bank Of Saurashtra Creation Date: 20 Jan 2005 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Elam Pharma?
Elam Pharma has a workforce of 7 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elam Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elam Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
